Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2024 | Is there a prodromal phase in MOGAD or NMOSD?

Dalia Rotstein, MD, MPH, St. Michael’s Hospital and the University of Toronto, Toronto, ON, discusses a study investigating a potential prodromal phase before the onset of clinical symptoms for patients with neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). This is based on patient reports of non-specific neurological symptoms before diagnosis. The study investigated health service use five years before diagnosis in patients with MOGAD and NMOSD, compared to matched controls. The research reveals increased health service utilization two years pre-diagnosis among patients with NMOSD but not those with MOGAD. These findings suggest a potential prodromal phase in NMOSD, warranting further investigation through biomarker assessment in pre-diagnosis blood samples, potentially opening avenues for preventive interventions. This interview took place during the annual ACTRIMS Forum 2024.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dalia Rotstein reports the following disclosures: I have received research support from MS Canada, the National MS Society, CMSC, University of Toronto Division of Neurology, and Roche Canada. I have received consulting or speaker fees from Alexion, Amgen, Biogen, EMD Serono, Novartis, Roche and Sanofi Aventis.